Company intelligence / Profile preview
Rapafusyn Pharmaceuticals
Baltimore, Maryland, United Statesrapafusyn.com ↗
- Ownership
- Private
- Employees
- ~12
- Development stage
- Preclinical
01
Overview
Rapafusyn has demonstrated the ability of its RapaGlue™ platform to rapidly generate novel non-degrading molecular glues that form ternary complexes with disease-relevant proteins. These compounds have shown promise in modulating previously undruggable protein-protein interactions and other challenging intracellular or membrane targets. All programs remain at the preclinical stage; no clinical results have been reported as of May 2025.[2][6][9]
- Therapeutic areas
- OncologyImmunologyCardiovascular
- Modalities
- Non-degrading molecular glues (macrocyclic peptides)[1][2]Small molecules (macrocycles)[3]
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Beyond the preview
Go deeper on Rapafusyn Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rapafusyn Pharmaceuticals.